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Background: Celiac disease (CD) is an autoimmune disorder that occurs in genetically predisposed people and is
caused by a reaction to the gluten protein found in wheat, which leads to intestinal villous atrophy. Currently there
is no drug for treatment of CD. The only known treatment is lifelong gluten-free diet. The main aim of this work is
to develop a mathematical model of the immune response in CD patients and to predict the efficacy of a
transglutaminase-2 (TG-2) inhibitor as a potential drug for treatment of CD.
Results: A thorough analysis of the developed model provided the following results:
1. TG-2 inhibitor treatment leads to insignificant decrease in antibody levels, and hence remains higher than in
healthy individuals.
2. TG-2 inhibitor treatment does not lead to any significant increase in villous area.
3. The model predicts that the most effective treatment of CD would be the use of gluten peptide analogs that
antagonize the binding of immunogenic gluten peptides to APC. The model predicts that the treatment of CD
by such gluten peptide analogs can lead to a decrease in antibody levels to those of normal healthy people,
and to a significant increase in villous area.
Conclusions: The developed mathematical model of immune response in CD allows prediction of the efficacy of
TG-2 inhibitors and other possible drugs for the treatment of CD: their influence on the intestinal villous area and
on the antibody levels. The model also allows to understand what processes in the immune response have the
strongest influence on the efficacy of different drugs. This model could be applied in the pharmaceutical R&D arena
for the design of drugs against autoimmune small intestine disorders and on the design of their corresponding
clinical trials.
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Celiac disease (CD) is an autoimmune disorder caused
by the gluten protein contained in many grains. Upon
entry of gluten into the small intestine, a patient de-
velops painful digestion disorders due to villi impairment
and loss of absorption. CD is partially a heritable disease
[1]. The gene implicated in predisposition to CD (HLA
DQ2 and DQ8) has a worldwide prevalence of around
1%. At present there is no therapeutic agent to treat this
disorder. The only approach able to minimize the CD* Correspondence: demin_jr@insysbio.ru
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reproduction in any medium, provided the orsymptoms and currently used as prophylaxis is the strict
compliance to a gluten-free diet (GFD), which consists
on the removal of all gluten containing products, such
as starchy and pasta from the diet, or the exchange of
these products for products with a reduced gluten con-
tent [2]. Similar to many other autoimmune diseases,
CD involves innate and adaptive immune responses
[3,4]. The innate response causes a primary impairment
of villi in the small intestine, increasing epithelial perme-
ability allowing the entry of proteins from the lumen to
the lamina propria [1]. The adaptive immune responseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in the intestinal lamina propia to antigen-presenting
cells (APCs) which leads to antibody production [1].
These peptides can undergo deamidation by the enzyme
tissue transglutaminase (TG-2) [1], which in genetically
predisposed individuals can boost the peptide immuno-
genicity [5,6]. This deamidation process enables the
APCs to take up not only immunogenic peptides but
also TG-2-peptide complexes. As a consequence, anti-
bodies are produced not only against gluten peptides but
also against TG-2 [7-10]. The two markers of CD are a
decline in the villous area of the small intestine (i.e. vil-
lous breakdown), and the appearance of anti TG-2 anti-
body in plasma. This suggests that TG-2 is a key
component of the disease and therefore a potential tar-
get candidate for CD therapy. Nevertheless, there are
many unexplored aspects in CD pathogenesis such as
breakdown of oral tolerance and non DQ2/DQ8 ways of
adaptive immune response stimulation.
To describe all intra- and extracellular processes asso-
ciated with a disease and integrate heterogeneous sets of
experimental data, a Quantitative Systems Pharmacology
(QSP) modeling approach can be employed. This ap-
proach enables the description of a general mechanism
of the immune response and its integration into the
regulatory mechanisms characteristic of a disease of
interest, in the current case CD. In addition, the QSP
modeling approach provides a way for integrating the
experimental data into a model to appropriately describe
the disease of interest; with the aim of evaluating the
most important processes and predicting potential tar-
gets for therapy.
A mathematical model of CD or its immune response
has not yet been described in the literature. However,
the mathematical modeling of a general immune re-
sponse has been extensively performed and described,
in particular the adaptive immune response, i.e. antigen
presentation, synthesis, and activity of antibodies. The
majority of the examples in the literature only describe
general trends of the adaptive immune response to an
antigen, without taking into account the complex regu-
latory mechanisms associated to the specific disease
[11-14]. Just a limited number of publications focus on
the adaptive immune response in the context of a dis-
ease mechanism in particular those induced by bacter-
ial agents [15,16]. The work presented here intends to
fill in these gaps by constructing a model of the innate
and adaptive immune responses in CD. This model in-
tegrates all the human in vitro, ex vivo and in vivo data
available, enabling the prediction of the efficacy of a
TG-2 inhibitor, as well as the effect of other possible
therapeutic agents on the levels of anti-TG-2 anti-
bodies in plasma, and on the villous area in the small
intestine.Methods
Available experimental data, facts and assumptions used
for model development
The model was constructed on the basis of the following
experimental and literature information:
1) Healthy subjects do not have DQ2/DQ8 APCs [1].
2) Gluten peptides bind to receptors of intestinal
epithelial cells (IEC), thus inducing zonulin synthesis
that breaks down tight cell junctions [17,18].
3) CD patients have a high level of intraepithelial
lymphocytes (IEL), including activated IELs [19,20].
4) Natural killers induce IEC apoptosis [21-23].
5) CD patients have an elevated level of interleukin-15
(IL-15) [24].
6) IL-15 promotes differentiation of APCs from
monocytes, stimulates activation of IELs and arrests
their apoptosis [24-26].
7) T helpers of type 1 and type 17 are the main types
of T-cells in adaptive immune response [1,27-29].
8) CD patients have an elevated level of interferon γ
(IFN-γ) in comparison to healthy individuals [30].
9) CD patients have an increased level of interleukin-21
(IL-21) relative to healthy individuals [31,32].
10) IFN-γ triggers IEC apoptosis [33].
11) IL-21 triggers IEC apoptosis [33].
12) IFN-γ and IL-21 are synthesized by activated Т-
cells and activated IELs, i.e. natural killers [33-35].
13) CD patients test is positive for antibodies to gluten
peptides and to TG-2 [10].
14) Antibodies to gluten peptides and TG-2 induce IEC
apoptosis and inhibit their maturation [36].
15) CD patients have higher constitutive expression of
IL15 receptor alpha in comparison with healthy
subjects [37]. Binding of IL-15 to these receptors
leads to IEL activation
16) The threshold of IEL activation by IL-15 is lower in
CD patients than that in healthy subjects [37-39].
17) CD patients have higher zonulin level in
comparison with healthy subjects [40,41].
In the development of this model the following
assumptions were made:
a) T-helpers of types 1 and 17 are combined in one
variable which is designated as T-cells.
b) Since the synthesis and degradation rates of IFN-
γ and IL-21, as well as their action on IEC death
are similar, IFN-γ and IL-21 were merged into a
single variable named as IF-21. The IF-21
synthesis rate was defined as combination of IFN-
γ and IL-21 synthesis velocities, and the IF-21
degradation rate was set to the average between
IFN-γ and IL-21 degradation rates (see the
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(5), (15)-(17)) and adaptive (based on clause (1))
immune responses in healthy subjects. In the
model describing healthy subjects IEC activation,
IEL activation velocities are equal to zero and
there are no differential equations for APC with
DQ2/DQ8 histocompatibility complex. As a
result, level of all activated cells, cytokines,
zonulin and antibodies are equal to zero for
healthy subjects.
d) The permeability of intestinal wall depends on
zonulin level and number of IEC. Velocity of
gluten peptides transport through intestine wall is
equal to zero when there is no zonulin and level
of IEC corresponds to healthy subject level. The
influence of zonulin and IEC is described in
additive manner (for more details see Additional
file 1).
e) To take into account a delay in antibody
production caused by T cells activation [42] and
affinity maturation of B cells [43], a transient step
in T-cell activation was introduced.
f ) The arrival of gluten peptides into the lumen of
healthy subjects and celiac disease patients on
gluten-containing diet was considered constant
rather than discrete and at a rate of 3 times per
day, which would correspond to a normal daily
food intake. It was set to the average inflow in a
patient following a GFD diet, which according to
the Codex Draft Revise Standard (2000) shouldure 1 Network of processes of innate and adaptive immune responses d
vation (reaction #11) velocities are equal to zero and there are no differentialcontain less that 20 ppm of gluten for foodstuffs
naturally gluten-free (GF) and less than 200 ppm
for foodstuffs rendered gluten-free (GF) [44].Scheme of the processes
Based on the experimental data and assumptions stated
above a network of processes was built, describing in-
nate and adaptive immune responses in CD patients
(Figure 1). The innate immunity cascade begins with the
binding of gluten peptides to IEC receptors (reaction #5),
thus activating them (see clause (2) in the previous sec-
tion). These activated IECs produce zonulin and release it
into the lumen (reaction #31) and IL-15 into the lamina
(reaction #7) respectively. Zonulin promotes the disrup-
tion of tight junctions that control the permeability of
macromolecules through the intestinal epithelial barrier
(reaction #13) (see clause (2)). IL-15 activates the IELs and
inhibits their apoptosis (reaction #10 and #11) (see clause
(6)). In accordance with clause (4) of the previous section,
the activated IELs (natural killers) induce IEC apoptosis
(reactions #4 and #6) and release various toxic proteins
(granzymes, perforins, etc.). In addition, activated IELs
produce IFN-γ and IL-21 (reaction #23) that also trigger
IEC apoptosis (reactions #4 and #6) (see clauses (10)-
(12)). The disruption of the tight junctions and IEC death
lead to the impairment of the epithelial barrier and an in-
crease of its permeability, which allows the gluten peptides
in the lumen to enter the lamina (reaction #13).
When the peptides reach the lamina propria they
can undergo deamidation by TG-2 [1] (reaction #33).escribed in the model. IEC activation (reaction #5), IEL
equations for DQ2/DQ8 APC in the model for healthy subjects.
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peptides [5,6,45,46]. IL-15, synthesized by activated IECs,
stimulates the conversion of dendritic cells and monocytes
into APCs with the definite histocompatibility complex
DQ2/DQ8 (reaction #16) (see clause (6)). These APCs
bind both native and deamidated gluten peptides as well
as deamidated gluten peptides complexed to TG-2 [1]
(reaction #18). As a result, TG-2 also becomes an anti-
gen. Deamidated gluten peptides are more potent in
APC activation than native peptides [5,46]. Those APCs
that have taken up the antigen become activated,
starting the production of IL-15 (reaction #7) and
stimulating T-cell activation (reaction #22 and #34)
[33]. The activated T-cells synthesize IFN-γ and IL-21
(reaction #23) that in turn activate more T-cells (reac-
tion #22), forming a positive feedback loop. In addition,
those activated T-cells (Т-helpers types 1 and 17) con-
siderably stimulate the production of antibodies specific
to TG-2 and gluten peptides (reaction #25), which in
turn trigger the apoptosis of IECs and inhibit their mat-
uration (reaction #3, #4 and #6) [1,35,36].
Model description
All processes of immune response are described as sys-
tem of ordinary differential equations:
dx
dt
¼ N⋅v; x 0ð Þ ¼ x0
Here, x = [x1,…,xm]
T is vector of model variables con-
centrations, x0 = [x10,…,xm0]
T is vector of initial concen-
trations of model variables, v = [v1,…,vn]
T is vector of
reaction rates, N is stoichiometric matrix which has n col-
umns and m rows. Detailed description of system of differ-
ential equations and reaction velocities are presented in
Additional file 1.
Overall, the model has a total of 16 variables and 54
parameters. Variables are listed in Additional file 1:
Table S1. Parameters, their values, and a description of
the source from which the values were obtained are
presented in section “Identification of model parame-
ters” and listed in Additional file 1: Table S2.
Identification of model parameters
As stated in the section “Scheme of the processes” the
reaction rate expressions contain 54 parameters. A por-
tion of these parameters was either taken directly from
literature sources or estimated from literature data.
Seventeen parameters were determined via the latter ap-
proach, amongst them the death constant of APCs, the
degradation constant of gluten peptides, the dissociation
constant of gliadin from IEC receptors, and the por-
tion of receptors to be occupied by gluten peptides to
activate IECs. Values of 2 parameters were assumedand 4 parameters were calculated using experimental
data. These parameters and their corresponding values are
given in Additional file 1: Table S2. The other 31 parame-
ters were evaluated based on the best fitting to the appro-
priate experimental data, using the Hook-Jeeves method
as implemented in the DBSolve Optimum package
[47,48]. As a criterion of goodness of fit, the sum of






Where n is the total number of experimental points, vi
is the experimentally measured value of the variable or
reaction rate, vi is the corresponding value estimated
from the model, kj, Kj are unknown parameters. To esti-
mate the values of the unknown parameters, the error
function (f ) was minimized.
Given the large number of unknown parameters
contained in the model, it was necessary to fit them
against the maximum possible experimental data points
and calculate the range of possible parameter values.
Therefore data was extracted from in vitro and ex vivo
studies, as well as clinical studies in patients at various
stages of CD, and 95% confidential intervals were calcu-
lated for fitted parameters using method described in
[49] (see Additional file 1: Table S2).
Results
Model validation
The appropriate choice of model parameters was veri-
fied against independent data that had not been used in
the identification of the model parameters. In fact, it is
known that after changing over from a gluten-containing
diet to a gluten-free diet the antibody level drops to the
background level (in the model to zero level) within 2 to
4 months [50]. After changing over from a GFD to a
gluten-containing diet, antibodies appear within 2 to
4 weeks [51]. Simulations of these two scenarios led to
the following predictions: (i) after changing over from a
gluten-containing diet to a GFD the antibody level
drops nearly to zero within 2 to 3 months (Figure 2), (ii)
after changing over from a GFD to a gluten-containing
diet antibodies appear within 2 weeks (Figure 3). These
temporal characteristics of transient processes, based on
model calculations, are consistent with clinical data.
Prediction of efficacy of various potential drugs to treat
celiac disease
The model developed herein was used to predict the TG-2
inhibitor activity and other potential therapeutic agents
for CD such as antibodies against IFN-γ and IL-15, gluten
peptide-related agents that arrest activation of APCs
(DQ2 blocking peptide analogues) [52-55], and gluten
peptide-related agents that repress IEC activation (perme-
ability inhibitors) [56]. The efficacy of each therapy was
Figure 2 Decreasing of antibodies level after changing diet from gluten-containing to gluten-free.
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levels. The antibody level was measured as a percentage,
whereby 100% corresponds to the steady-state level of a
patient on a gluten-containing diet. For a patient on a
GFD and for a healthy patient the antibody levels are close
to and equal to zero, respectively.
TG-2 inhibitor
To model the activity of a TG-2 inhibitor, the TG-2 level
in the lamina propria was decreased. It was found that
when the TG-2 level reaches zero, i.е. upon complete in-
hibition, the antibody levels only decrease to 70-75%
(Figure 4a). Likewise, the complete inhibition of TG-2
does not cause a significant increase in the villous area:
from 10 to 14% (Figure 4b).
Next, an analysis was performed to determine what
processes most significantly influence the efficacy of
TG-2 inhibitors. It turned out that the most important
process was the activation of APCs and B-cells by pep-
tides binding to it. It is known from the literature that
the ЕС50 of APC activation by deamidated peptides is
5-fold lower than by native peptides, i.e. deamidated
proteins are more immunogenic [5,6]. However, theseFigure 3 Appearance of antibodies after changing diet from gluten-frdata cannot be considered unambiguous since the ratio
of ЕС50 between deamidated and native forms varies
with different gluten peptides [6]. So a series of simula-
tions was run where the ЕС50 of the deamidated pep-
tides was fixed and the EC50 of the native peptides was
expressed as an increasing n-fold value of it. Every time
the native to deamidated ЕС50 ratio was increased, the
model was re-validated ( kabs was increased) since the
antibody level declined due to a reduction in the im-
munogenicity of the native peptides. Overall, by in-
creasing the native to deamidated ЕС50 ratio, the role
of TG-2 in the immunogenicity of peptides becomes
more important. The results shown that the antibody
levels drop to or near zero at ratio values of 80-fold or
greater (Figure 5), and no significant expansion of the
villous area was observed.
IFN-γ antibodies
To model the activity of IFN-γ antibodies, the degrad-
ation rate constant of IF-21 (IFN-γ + IL-21) was in-
creased. As a result, considering the maximum possible
breakdown rate (i.e. when the IF-21 concentration de-
creased to zero) the antibody levels dropped to 83%ee to gluten-containing.
Figure 4 (a) Decreasing of antibodies level during treatment by different potential therapeutic agents; (b) Increasing of VA during
treatment by different potential therapeutic agents (Curve for Permeability inhibitor coincides with curve for TG2 inhibitor).
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(Figure 4b).IL-15 antibodies
To model the activity of IL-15 antibodies the degradation
rate constant of IL-15 was increased. At the maximum
possible degradation rate (i.e. when IL-15 concentration
decreased to zero) the antibody levels dropped to 69%Figure 5 Decreasing of antibodies level during TG-2 inhibitor treatme(Figure 4a) and the villous area increased up to 46%
(Figure 4b).
Gluten peptide-related agents that repress IEC activation
(permeability inhibitors)
To model the activity of gluten peptides analogues the
activation rate constant of IECs was set to zero. Conse-
quently the antibody levels dropped to 92% (Figure 4a)
and the villous area increased up to 14% (Figure 4b).nt at different EC50 ratio.
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(DQ2-blocking peptide analogues)
To model the activity of these analogues of gluten pep-
tides the activation rate constant of APCs was set to
zero. Consequently, the antibody levels dropped to zero
(Figure 4a) and the villous area increased up to 51%
(Figure 4b).
Discussion
CD is a complex autoimmune disorder with many unex-
plored aspects. Role and contribution of various possible
mechanisms (disruption of “central”, “peripheral” toler-
ances, T cell anergy, etc.) to oral tolerance breakdown,
CD pathogenesis and severity is not established yet.
There are different possible ways of gluten peptides
transfer into the lamina propria [57]. They could cross
the intestinal epithelium either via the paracellular route
or via the transcellular route. In the first case this occurs
as a consequence of an increased permeability, in the
second case it occurs by using enterocytic vesicles that
are able to cross the basal membrane allowing intact
gluten peptides to have access to the lamina propria. It
is known that one of the main cause of CD is the pres-
ence of HLA DQ2 and DQ8 molecules, but 1-2% of CD
patients do not have DQ2 and/or DQ8 [51]. So there
could be non DQ2/DQ8 ways of immune response
stimulation. In our model the mechanism of oral toler-
ance breakdown has not been considered. We take into
account only DQ2/DQ8 route of immune response
stimulation and paracellular way of gluten peptides
transfer into lamina propria. To describe healthy pa-
tients we use the assumption that there are no innate
and adaptive immune responses in healthy subject (see
section “Methods”). This approach allows us to simplify
the equations of our model and to decrease the number
of model parameters. The detailed description of mecha-
nisms of IEL activation, transport of gluten peptides
through intestine wall, interaction of peptides with non
DQ2/DQ8 APC in healthy subjects could help to study
and understand more clear the processes underlying the
absence of immune responses in healthy subjects. This
could be the next step for modeling of immune response
in human.
The model described in this manuscript was able to
predict that a TG-2 inhibitor can reduce the antibody
levels down to zero if the deamidated peptides are more
immunogenic than the native peptides, i.e. if the ЕС50
of deamidated peptides binding to APCs and B-cells is
80-fold lower or less than for native peptides. However,
a TG-2 inhibitor would not significantly increase the vil-
lous area because the influence of antibodies on IEC
death and inhibition of their maturation is insignificant.
This is logical given that the villous area in a patient on
a GFD was experimentally shown to be 50% of that in ahealthy patient. It is known that in a patient following
GFD the antibody levels are similar to the background
antibody levels of a healthy patient (i.e. it equals to zero
in the model). It follows from this that a 2-fold reduc-
tion in the villous area (from 100% to 50%) is due to
IELs and IFN-γ, to a lesser extent, zonulin. After chan-
ging over from GFD to gluten-containing diet, the vil-
lous area decreases from 50% to 10%. This can be
attributed to an increase in the levels of IELs and IFN-γ
that trigger IEC apoptosis, as well as to the action of IL-
21 and the antibodies. Overall, even if one suggests that
the reduction from 50% to 10% only occurs through
antibodies, then upon the condition that deamidated
peptides are significantly more immunogenic than native
ones (the ЕС50 ratio is 1:80 or greater), the TG-2 inhibi-
tor induces a state similar to that of a GFD (in terms of
both the antibody level and the villous area).
An evaluation of the efficacy of various potential drugs
to treat CD suggests that the most efficient therapeutic
agents would be analogues of immunogenic peptides
that repress activation of APCs. This is logical as acti-
vated APCs play a key role in the adaptive immune re-
sponse and maintenance of the activity of effectors of
the innate immune response. Activated APCs release IL-
15 that in turn arrests IELs death and at the same time
induce their activation, i.e. stimulates differentiation of
natural killers from IELs triggering apoptosis. As a con-
clusion, by arresting APC activation it seems that the
synthesis of antibodies can be completely shut down and
the concentrations of activated IELs, IFN-γ, and IL-21
significantly decreased, resulting in an increase of the
villous area up to 51%.
One type of promising agents for CD therapy, the ana-
logues of immunogenic peptides that repress IEC activa-
tion, appeared to be less efficient than GFD. These
analogues arrest IEC activation, which represses the syn-
thesis of zonulin and IL-15. However, this has no signifi-
cant effect on effectors of the adaptive immune
response. Activated APCs continue the synthesis of IL-
15, activating IELs and T-cells, both of which trigger the
release of IFN-γ and IL-21. The antibody level, which
depend directly and exclusively on the number of acti-
vated T-cells and the amount of gluten peptides in the
lamina propria, remain nearly the same as in the absence
of peptide analogues. The villous area, increases only up
to 14% due to the absence of zonulin, and a limited re-
duction in the concentration of activated IELs, IFN-γ
and IL-21.
Significant reduction in IFN-γ and IL-15 level (resulted
from administration of corresponding specific anti-
bodies, for example) leads to the small decrease in anti-
body level. This can be explained in terms of auxiliary
role of the cytokines in adaptive immune response.
Indeed, IFN-γ is involved in T cells activation and
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activation by some extent but even complete depletion
of IFN-γ does not lead to stop in T cell activation. IL-15
is involved in differentiation of APCs from monocytes.
Elevation in IL-15 is able to increase the rate of differen-
tiation of APCs from monocytes but there is other IL-15
independent ways of replenishment of APC population.
At the same time, decrease in IFN-γ and IL-15 levels re-
sults in significant increase of villous area (up to 40%
and 46% respectively) because of the significant influ-
ence of IFN-γ and IL-21 on IEC apoptosis and strong
stimulation effect of IL-15 on IEL activation.
The robustness of model predictions was analyzed in
the following manner. We simulated villous area and
antibody level during different treatments taking the
value of model parameters from the confidential inter-
vals identified using method described in section “Simula-
tions on the range of parameter’s confidential intervals”
(Additional file 1). Results are presented in Additional
file 1: Figure S15-24. From the analysis we can con-
clude that model predictions of influence of TG-2 in-
hibitor, permeability inhibitor, DQ-2 blocking peptides
on villous are and antibody level and IFN-γ, IL-15 anti-
bodies on antibody level are quite robust to variation in
model parameters. On the other hand, robustness of
the model predictions for IFN-γ (Additional file 1:
Figure S22) and IL-15 (Additional file 1: Figure S23)
antibodies influence on villous area is not satisfactory.
This can be explained in terms of lack of sufficient
amount of available experimental data required for reli-
able identification of parameter values responsible for
the processes associated with contribution of IFN-γ and
IL-15 to immune response in CD. This pushes us to
state that model of celiac disease developed in our
manuscript can be applied to identify gaps in experi-
mental and clinical data and to initiate more quantita-
tive and rational exploration of the processes involved
in CD pathogenesis. Taking these gaps in experimental/
clinical data in mind model can advise on optimal de-
sign of clinical study or experiment [58,59].Conclusions
Overall, the use of antibodies against IFN-γ, and IL-15,
analogues of gluten peptides repressing IEC activation,
and TG-2 inhibitor would not be efficient solutions to
treat CD. The model indicates that the most efficient
therapeutic agent is a product that acts on species in-
volved in both the innate and the adaptive immune re-
sponse, i.e. analogues of gluten peptides that arrest APC
activation. This model could be applied in the pharma-
ceutical R&D arena for the design of drugs against auto-
immune small intestine disorders and on the design of
their corresponding clinical trials.Additional file
Additional file 1: Detailed description of the model system of
differential equations, rate laws and model verification. List of model
parameters and variables.
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